INTRODUCTION
============

Children with Down syndrome are predisposed to developing acute leukemia. The most common leukemia associated with Down syndrome is acute megakaryoblastic leukemia (AMKL), and the incidence is approximately 500-fold higher than in healthy children ([@B1]). Transient myeloproliferative disorder (TMD) is a leukemoid reaction occurring occasionally in Down syndrome newborn infants, and is characterized by the rapid growth of abnormal blast cells expressing megakaryocytic markers. Although most TMD cases resolve spontaneously, AMKL develops in approximately 20% to 30% of TMD cases in the first 4 yr of life, often preceded by a myelodysplastic phase. Recently, acquired mutations in the N-terminal activation domain of the *GATA1* gene, encoding a zinc-finger transcription factor that regulates the normal development of the megakaryocytic, erythroid, basophilic/mast cell and eosinophilic lineages, have been reported in TMD and Down syndrome-related AMKL (DS-AMKL) ([@B2]). Two isoforms of GATA-1 protein are usually detected: a full-length GATA-1 translated from the first start codon ATG on exon 2, and a 40-kDa shorter form, GATA-1s that initiated from an ATG on exon 3. Most of the mutations in TMD and DS-AMKL were located in the regions including exon 2 and an identical mutation in specimens from TDM and AMKL have been found in Down syndrome patients ([@B3]-[@B8]). The mutation results in the introduction of a premature stop codon in the gene sequence that encodes the N-terminal activation domain, and a lack of expression of the full-length GATA-1.

Here we describe a 3-yr-old girl patient with DS-AMKL, who was found to have a novel *GATA1* gene mutation and complex cytogenetic aberrations including constitutional trisomy 21, clonal monosomy 7, and an additional copy of chromosome 21. To the best of our knowledge, this is a first case of DS-AMKL with a *GATA1* gene mutation described in Korea. This case indicate that expression of an abnormal GATA-1s with a defective N-terminal activation domain, in the absence of full-length GATA-1, and that other genetic changes contribute to the development of DS-AMKL, previously described in Caucasians and now in a Korean patient.

CASE REPORT
===========

A 3-yr-girl patient with Down syndrome was admitted because of pallor and fever. Initial laboratory tests showed Hb 2.7 g/dL, WBC 9.77×10^9^/L, and platelets 7×10^9^/L. A peripheral blood smear revealed that 52% of the white blood cells were blasts with a round nucleus with fine reticular chromatin, one to three nucleoli and cytoplasmic bleb, and the bone marrow aspirate smear revealed that the blasts were counted at 73% ([Fig. 1A](#F1){ref-type="fig"}). Flow cytometric analyses showed that these blasts were CD13+, CD33+, CD34+, HLA-DR+, CD61+, and aberrant CD7+. A cytochemical stain showed reactivity with CD61 and punctuate nonspecific esterase reactivity and negativity for sudan black B and peroxidase; the blasts were compatible with the features of megakaryoblasts ([Fig. 1B](#F1){ref-type="fig"}). Cytogenetic analysis of the bone marrow cells revealed 48,XX,-7,+21c,+21,+r\[3\]/47,XX, +21c\[17\] ([Fig. 2A](#F2){ref-type="fig"}). We analyzed the *GATA1* mutation in this patient after obtaining informed consent from the parents. The genomic DNA was isolated from the bone marrow leukocytes using a Wizard genomic DNA purification kit following the manufacturer\'s instruction (Promega, Madison, WI, U.S.A.). The *GATA1* gene was amplified by use of the polymerase chain reaction (PCR) with use of the appropriate primers (available upon request) and a thermal cycler (Model 9700, Applied Biosystems, Foster City, CA, U.S.A.). Direct DNA sequencing was performed with the BigDye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems) on an ABI Prism 3100 genetic analyzer (Applied Biosystems). Following *GATA1* gene mutation analysis, a novel mutation, c.145dupG (p.Ala49GlyfsX18), was identified in the N-terminal activation domain, exon 2 of *GATA1* ([Fig. 3](#F3){ref-type="fig"}). This mutation resulted in a premature stop codon at amino acid 67 and resulted in the production of GATA-1s. The parents of the patient denied a history of TMD. A final diagnosis was confirmed as DS-AMKL. The patient received intensified induction chemotherapy (daunorubicin 45 mg/m^2^ with cardioxane, cytosine arabinoside 100 mg/m^2^, and intrathecal cytosine arabinoside 30 mg) and achieved complete remission on day 28. The follow-up studies on day 28 revealed cytogenetic and morphological remission. The leukemia relapsed under the course of the consolidation chemotherapy, 11 months later. The blasts reappeared on a peripheral blood smear and bone marrow aspirate smear, and represented up to 34% of the white blood cells and 49% of all of the nucleated cells, respectively. Flow cytometric analyses showed the same results as the initial leukemic clone. Cytogenetic analysis with bone marrow cells revealed only constitutional trisomy 21 (47,XX,+21c\[20\]) ([Fig. 2B](#F2){ref-type="fig"}). Although the peak of the mutated *GATA1* gene sequence of the specimen taken after relapse was lower than that of the initial specimen, the same mutation was detected after relapse.

DISCUSSION
==========

Recently, acquired mutations in the *GATA1* gene that have been reported in nearly all cases of TMD and DS-AMKL have been shown to be specific for DS-AMKL ([@B3], [@B7]). *GATA1* mutations are present in blasts of TMD and show the identical *GATA1* mutation in sequential samples collected from a patient during TMD, and subsequently AMKL. These findings suggest a model of malignant transformation in DS-AMKL in which *GATA1* mutations are an early event and AMKL arises from latent TMD clones following initial apparent remission ([@B9]). The mutation expresses only a truncated mutant of the *GATA1* gene and a short form of the protein, GATA-1s, is produced. Full-length GATA-1 induces differentiation toward the erythroid/megakaryoblastic lineage. However, expression of GATA-1s did not induce erythroid/megakaryoblastic differentiation. These results indicate that expression of only GATA-1s with a defective N-terminal activation domain contributes to the expansion of TMD blast cells, and that other genetic changes contribute to the development of AMKL in Down syndrome ([@B7], [@B9]).

Down syndrome of this patient was recognized by the physician at admission. This patient had no known clinical history of TMD. The *GATA1* mutation may be present at birth in many cases in patients without known clinical TMD, and who later develop AMKL ([@B6]). Unfortunately, we did not confirm the presence of the same *GATA1* mutation at birth in this case. After relapse, the same *GATA1* mutation was detected.

Studies on TMD or AMKL in Down syndrome are especially lacking for Korean patients.

The detection of *GATA1* mutation is highly suggestive of DS-AMKL, and is important in the understanding Down syndrome-related leukemogenesis, and a new target for the detection of minimal residual disease ([@B10]). For children with no obvious symptoms of Down syndrome, detection of a *GATA1* mutation is highly informative to distinguish between DS-AMKL and a non-Down syndrome AMKL. However, *GATA1* mutations are not associated with every case of DS-AMKL. This may be due to a technical limitation in detecting a *GATA1* mutation in a sample with a low blast population, or alternatively, an indication that a separate class of DS-AMKL exists. While *GATA1* mutations have been detected in children diagnosed with DS-AMKL as old as 50 months, very few cases of children older than 4 yr have been studied to be significant ([@B8]). Children older than 4 yr and with the absence of a *GATA1* mutation in DS-AMKL face the worst prognosis. Further studies into the potential use of *GATA1* mutation analysis for the diagnosis of DS-AMKL are therefore needed.

*GATA1* mutations have been found in otherwise healthy Down syndrome neonates at birth, that have not yet developed TMD or AMKL ([@B6]). These findings suggest that acquired mutations in *GATA1* and the generation of GATA-1s cooperate frequently with trisomy 21 in initiating megakaryoblastic proliferation, but are insufficient for the progression to AMKL. Mutagenesis of *GATA1* is an initiating event in Down syndrome-associated leukemogenesis. *GATA1* mutations have not been found in non-Down syndrome patients with leukemia of any kind, with the following exception. Children without Down syndrome, but with acquired trisomy 21, trisomy 21 mosaicism, or tertasomy 21 in their leukemic cells, may, on rare occasions, present with AMKL that harbors a *GATA1* mutation ([@B11]). Therefore, increased expression of certain chromosome 21 genes in the same cell that carries the *GATA1* mutation may enhance its proliferation and survival ([@B12]). There are several genes on the small chromosome 21 that encode proteins that may enhance megakaryopoiesis. These genes include *RUNX1/AML1* ([@B13], [@B14]), *ERG* ([@B15]), *Ets2*, and a newly discovered group of genes coding for regulatory micro-RNAs ([@B12], [@B16]). *ERG* is an Ets transcription factor and excess expression of *ERG* in hematopoietic progenitor cells, coupled with a differentiation arrest is caused by the acquisition of mutations in *GATA1* ([@B15]). Overexpression of *ERG*, perhaps in conjunction with other factors such as *Ets2*, may contribute to expanded megakaryopoiesis cells harboring trisomy 21. *RUNX1/AML1* is known to be the most frequent target for a chromosomal translocation in leukemia. Recently, point mutations in the Runt domain of the *AML1* gene have also been reported in cells from leukemia patients ([@B17]). Interestingly, *AML1* mutations are frequently found in myeloid malignancies with acquired 21 trisomy ([@B18]). It has been suggested that increased RUNX1 activity has a role in DS-AMKL development due to the physical interaction and synergy between *GATA1* and *RUNX1* ([@B13]). To understand further the mechanisms of a lineage-specific malignant conversion, it is very important to identify the gene or genes on chromosome 21 that cooperate with mutated *GATA1* as well as additional genetic changes in TMD blast cells during the development of DS-AMKL. Therefore, the development of DS-AMKL requires at least three cooperating events-trisomy 21, a *GATA1* mutation, and a third, as yet undefined, additional genetic alteration ([@B16]).

Although acquired mutations in the *GATA1* gene have been reported in DS-AMKL in Caucasians, this is a first case of a Korean Down syndrome patient with AMKL carrying a novel mutation of *GATA1* gene. This case demonstrates that expression of the abnormal GATA-1s with a defective N-terminal activation domain, in the absence of full-length GATA-1, contributes to the development of DS-AMKL, as seen previously in Caucasians and now in a Korean patient. Large and prospective studies are needed to reveal *GATA1* mutations and additional genetic alternations, such as overexpression of *RUNX1/AML1* or *EGR*, for the development of DS-AMKL in Down syndrome patients.

![Bone marrow aspiration revealed that blasts were 73% (**A**) and cytochemical stain showed reactivity with CD61 and punctuate nonspecific esterase reactivity (**B**), and negativity on peroxidase and sudan black B.](jkms-23-1105-g001){#F1}

![Cytogenetic analysis of bone marrow cells revealed 48,XX,7,+21c,+21,+r\[3\]/47,XX,+21c\[17\] at initial diagnosis (**A**) and only constitutional trisomy 21 at relapse (**B**).](jkms-23-1105-g002){#F2}

![Direct DNA sequencing analyses of the *GATA1* gene revealed a novel mutation, c.145dupG (p.*Ala49GlyfsX18*), identified in the N-terminal activation domain of exon 2 of *GATA1*. This mutation produced a premature stop codon at amino acid 67 and expression of an abnormal short variant, GATA-1s, with a defective N-terminal activation domain, in the absence of the full-length GATA-1. The same mutation was discovered in a specimen taken following relapse.](jkms-23-1105-g003){#F3}
